— Why it moved
Why ICCM Stock More Than Doubled Today — June 17, 2026
A 70% install-base update hit a 1.5M-share float with half of it sold short — IceCure went from $4.60 to $9.54 in 47 minutes.
What moved ICCM stock
IceCure Medical makes ProSense, a breast-cancer cryoablation system that got FDA marketing authorization last October. It reported 70% growth in ProSense's active U.S. install base, plus fresh kidney-tumor data at ECIO showing roughly 90% recurrence-free outcomes. Real headlines — with a very small company underneath them.
The mechanics
The float is 1.5M shares on a ~$6M cap, and short interest sat near 49% of float. At that size the news barely matters: 151M shares traded, turning the float over about 100 times. Squeeze fuel plus a story equals vertical.
ICCM by the numbers
The alert window
Stock Pulse flagged it at 9:34 ET at $4.60. The top, $9.54, printed at 10:21 — forty-seven minutes later, 107% above the alert. A real-time reader had most of an hour while the stock doubled.
How ICCM's move ended
An afternoon retest of $9.47 failed, and it closed at $6.39 — still 39% above the alert but a third off the high; anyone chasing the morning top was down by the close. The same day it announced a $5.5M private placement, dilution nearly the size of its entire market cap, on a stock already 95% below its 52-week high.
The tell: a half-shorted micro-float turns good news into a squeeze — and the company selling shares into that squeeze tells you what it thinks the pop is worth.